Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLLNASDAQ:ENGNNASDAQ:PHVSNASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$27.00-2.2%$28.30$23.23▼$42.29$867.56M0.76442,564 shs232,582 shsENGNenGene$4.14+3.5%$4.72$3.50▼$16.25$211.05M-0.38131,306 shs24,049 shsPHVSPharvaris$18.48+7.0%$15.00$11.51▼$25.50$966.32M-2.8473,753 shs145,741 shsSYRESpyre Therapeutics$15.23+1.4%$16.15$10.91▼$40.49$918.00M3.05599,877 shs439,457 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+2.72%+2.64%-7.10%-14.87%-24.82%ENGNenGene+0.25%0.00%-6.98%-45.87%-74.52%PHVSPharvaris+1.23%+14.45%+9.30%-2.10%-26.35%SYRESpyre Therapeutics+2.39%+7.59%-16.28%-31.42%-56.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical4.0483 of 5 stars3.41.00.03.02.90.82.5ENGNenGene3.3862 of 5 stars4.53.00.00.01.92.50.6PHVSPharvaris2.1947 of 5 stars3.53.00.00.03.30.80.0SYRESpyre Therapeutics1.7938 of 5 stars3.60.00.00.02.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.80Moderate Buy$43.6061.48% UpsideENGNenGene 3.00Buy$23.29462.46% UpsidePHVSPharvaris 3.00Buy$39.00111.04% UpsideSYRESpyre Therapeutics 3.20Buy$49.57225.49% UpsideCurrent Analyst Ratings BreakdownLatest ENGN, COLL, PHVS, and SYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025ENGNenGeneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.004/29/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$28.004/9/2025COLLCollegium PharmaceuticalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/8/2025SYRESpyre TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/8/2025SYRESpyre TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$45.003/24/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/18/2025SYRESpyre TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$27.003/11/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.003/11/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.002/18/2025ENGNenGenePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$26.002/18/2025SYRESpyre TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.37$9.78 per share2.76$5.99 per share4.51ENGNenGeneN/AN/AN/AN/A$6.17 per shareN/APHVSPharvarisN/AN/AN/AN/A$7.95 per shareN/ASYRESpyre Therapeutics$890K1,031.46N/AN/A($0.22) per share-69.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$48.15M$1.8611.644.49N/A14.78%104.67%18.38%5/8/2025 (Estimated)ENGNenGene-$55.14M-$1.52N/AN/AN/AN/A-16.69%-14.27%6/10/2025 (Estimated)PHVSPharvaris-$109.18M-$2.68N/AN/AN/AN/A-38.52%-36.69%5/14/2025 (Estimated)SYRESpyre Therapeutics-$338.79M-$4.23N/AN/AN/AN/A-210.01%-44.40%5/8/2025 (Estimated)Latest ENGN, COLL, PHVS, and SYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PHVSPharvaris-$0.80N/AN/AN/AN/AN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50N/AN/AN/A$174.96 millionN/A5/8/2025Q1 2025SYRESpyre Therapeutics-$0.74N/AN/AN/AN/AN/A4/7/2025Q4 2024PHVSPharvaris-$0.74-$0.68+$0.06-$0.68N/AN/A2/27/2025Q4 2024COLLCollegium Pharmaceutical$1.54$1.63+$0.09$0.36$179.68 million$181.95 million2/27/2025Q4 2024SYRESpyre Therapeutics-$0.89-$0.81+$0.08-$0.81$2.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AENGNenGene$1.5838.19%N/AN/A N/APHVSPharvarisN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.430.970.88ENGNenGene0.0816.8716.87PHVSPharvarisN/A19.0819.08SYRESpyre TherapeuticsN/A7.327.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AENGNenGene64.16%PHVSPharvarisN/ASYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%ENGNenGene13.70%PHVSPharvaris11.84%SYRESpyre Therapeutics6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million30.97 millionOptionableENGNenGene3150.98 million38.16 millionN/APHVSPharvaris3052.29 million46.10 millionNot OptionableSYRESpyre Therapeutics10060.28 million48.24 millionOptionableENGN, COLL, PHVS, and SYRE HeadlinesRecent News About These CompaniesAdage Capital Partners GP L.L.C. Lowers Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)April 28 at 5:37 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 3.6% - Here's WhyApril 24, 2025 | marketbeat.comCapital World Investors Invests $8.81 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE)April 24, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3% - Still a Buy?April 23, 2025 | marketbeat.comB Group Inc. Buys Shares of 50,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE)April 23, 2025 | marketbeat.comGeode Capital Management LLC Buys 75,081 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)April 21, 2025 | marketbeat.comAffinity Asset Advisors LLC Purchases 325,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)April 17, 2025 | marketbeat.comFmr LLC Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)April 15, 2025 | marketbeat.comWhy Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 6.55%April 14, 2025 | aaii.comF M Investments LLC Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)April 14, 2025 | marketbeat.comVanguard Group Inc. Buys 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)April 13, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for SYRE Q1 Earnings?April 12, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Upgraded to "Strong-Buy" at Leerink PartnrsApril 11, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Now Covered by Leerink PartnersApril 10, 2025 | marketbeat.comSpyre Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:SYRE | BenzingaApril 9, 2025 | benzinga.comSpyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year Low - Here's What HappenedApril 9, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from AnalystsApril 9, 2025 | marketbeat.comLeerink Partners Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform RecommendationApril 8, 2025 | msn.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Wellington Management Group LLPApril 8, 2025 | marketbeat.comSchroder Investment Management Group Takes $2.56 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)April 8, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Holdings Lowered by Cinctive Capital Management LPApril 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season3 Stocks Presenting Generational Buying OpportunitiesBy Chris Markoch | April 25, 2025View 3 Stocks Presenting Generational Buying OpportunitiesHims & Hers Stock Soars on Novo Nordisk CollaborationBy Gabriel Osorio-Mazilli | April 30, 2025View Hims & Hers Stock Soars on Novo Nordisk CollaborationENGN, COLL, PHVS, and SYRE Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$27.00 -0.60 (-2.17%) As of 04:00 PM EasternCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.enGene NASDAQ:ENGN$4.14 +0.14 (+3.50%) As of 04:00 PM EasternenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Pharvaris NASDAQ:PHVS$18.48 +1.21 (+7.01%) As of 04:00 PM EasternPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Spyre Therapeutics NASDAQ:SYRE$15.23 +0.21 (+1.40%) As of 04:00 PM EasternSpyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
